AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20492507 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoquinone (40 mg)
Number of subjects: 30
Study 20492507 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoquinone (80 mg)
Number of subjects: 30
Study 20492507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 18096840 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive treatment with continuous intravenous insulin
Number of subjects: 46
Study 18096840 — intervention group
Group type: COMPARATOR
Intervention: Usual care with subcutaneous insulin QID as needed
Number of subjects: 46
Study 17199202 — intervention group
Group type: EXPERIMENTAL
Intervention: Anonymous STD counselling and comprehensive services
Number of subjects: 0
Study 17199202 — intervention group
Group type: COMPARATOR
Intervention: Obligatory VD checks for prostitutes
Number of subjects: 0
Study 14528773 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized local anesthesia (Wand)
Number of subjects: 102
Study 14528773 — intervention group
Group type: COMPARATOR
Intervention: Conventional syringe injection
Number of subjects: 102
Study 10599773 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrifonate (30 to 60 mg based on weight or a 50-mg fixed dose)
Number of subjects: 959
Study 10599773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 959
Study 10599773 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrifonate
Number of subjects: 959
Study 10599773 — intervention group
Group type: EXPERIMENTAL
Intervention: APOE genotype
Number of subjects: 959
Study 8846152 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 66
Study 8846152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 8846152 — intervention group
Group type: COMPARATOR
Intervention: Dietary advice
Number of subjects: 66
Study 8846152 — intervention group
Group type: COMPARATOR
Intervention: Non supplemented women
Number of subjects: 66
Study 8846152 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 66
Study 1663965 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (average dose 18.8 mg)
Number of subjects: 828
Study 1663965 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (average dose 37.4 mg)
Number of subjects: 828
Study 1663965 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 828
Study 1663965 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 828
Study 1663965 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (highest dose level)
Number of subjects: 828
Study 6104172 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT), administered three times a week, with a minimum of eight treatments and a maximum of twelve.
Number of subjects: 20
Study 6104172 — intervention group
Group type: COMPARATOR
Intervention: Control group (no electricity used, no convulsion induced), administered the same treatment procedure as ECT.
Number of subjects: 20
Study 30998792 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean meal (MdM)
Number of subjects: 39
Study 30998792 — intervention group
Group type: COMPARATOR
Intervention: Fast Food meal (FFM)
Number of subjects: 39
Study 28401197 — intervention group
Group type: EXPERIMENTAL
Intervention: PRF combined with a new split crest flapless modified technique (test group)
Number of subjects: 10
Study 28401197 — intervention group
Group type: COMPARATOR
Intervention: Traditional technique with deeper insertion of smaller implants (control group)
Number of subjects: 10
Study 26010803 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified preparation (300 mg of aspirin and 75 mg of clopidogrel bisulfate; with 200 mg of cilostazol added for HTPR to clopidogrel)
Number of subjects: 228
Study 26010803 — intervention group
Group type: COMPARATOR
Intervention: Standard preparation (100 mg of aspirin and 75 mg of clopidogrel)
Number of subjects: 228
Study 26010803 — intervention group
Group type: COMPARATOR
Intervention: Non-HTPR group
Number of subjects: 228
Study 26010803 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified preparation
Number of subjects: 228
Study 26010803 — intervention group
Group type: COMPARATOR
Intervention: Standard preparation
Number of subjects: 228
Study 24130381 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy (PPI and amoxicillin for 5 days followed by PPI, clarithromycin and tinidazole for 5 days)
Number of subjects: 2
Study 24130381 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (PPI, clarithromycin and amoxicillin for 10 days)
Number of subjects: 2
Study 24130381 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy
Number of subjects: 2
Study 24130381 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 2
Study 21823278 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint pressing
Number of subjects: 168
Study 21823278 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin
Number of subjects: 168
Study 21823278 — intervention group
Group type: COMPARATOR
Intervention: Suxiaojiuxin pill
Number of subjects: 168
Study 19620926 — intervention group
Group type: EXPERIMENTAL
Intervention: COMB - cold water immersion and active recovery using a cycle ergometer
Number of subjects: 28
Study 19620926 — intervention group
Group type: COMPARATOR
Intervention: CONT - cold (12 degrees C) water immersion and hot (38 degrees C) shower
Number of subjects: 28
Study 19620926 — intervention group
Group type: COMPARATOR
Intervention: PASS - a passive post-match routine (stretching and leg raise)
Number of subjects: 28
Study 16696841 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with learning disability
Number of subjects: 41
Study 16696841 — intervention group
Group type: COMPARATOR
Intervention: Age-matched controls without learning disability
Number of subjects: 41
Study 15595714 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal Assessment Battery (FAB) administered to patients with mild Alzheimer's disease (AD)
Number of subjects: 236
Study 15595714 — intervention group
Group type: COMPARATOR
Intervention: Frontal Assessment Battery (FAB) administered to normal controls
Number of subjects: 236
Study 15595714 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal Assessment Battery (FAB) administered to patients with frontotemporal dementia (FTD)
Number of subjects: 236
Study 11488449 — intervention group
Group type: EXPERIMENTAL
Intervention: Boswellia serrata gum resin (900 mg daily divided in three doses for 6 weeks)
Number of subjects: 30
Study 11488449 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine (3 gm daily divided in three doses for 6 weeks)
Number of subjects: 30
Study 11488449 — intervention group
Group type: EXPERIMENTAL
Intervention: Boswellia serrata gum resin
Number of subjects: 30
Study 11488449 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine
Number of subjects: 30
Study 9131764 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian and mixed Bayesian/likelihood approaches to sample size calculations
Number of subjects: 0
Study 8097788 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized pentamidine (AP), 60 mg biweekly via System 22 nebulizer
Number of subjects: 209
Study 8097788 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 209
Study 8097788 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized pentamidine (AP)
Number of subjects: 209
Study 3307496 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment specific for substance abuse
Number of subjects: 54
Study 3307496 — intervention group
Group type: COMPARATOR
Intervention: Control patients received nonspecific points
Number of subjects: 54
Study 29125197 — intervention group
Group type: EXPERIMENTAL
Intervention: Active RF‐EMF exposure (902‐928 MHz spread spectrum digitally modulated signal, average radiated power output of 1 W)
Number of subjects: 3
Study 29125197 — intervention group
Group type: COMPARATOR
Intervention: Sham RF‐EMF exposure
Number of subjects: 3
Study 28171220 — intervention group
Group type: EXPERIMENTAL
Intervention: LaVita® (micronutrient supplementation)
Number of subjects: 150
Study 28171220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 26553684 — intervention group
Group type: EXPERIMENTAL
Intervention: PsA‐TT
Number of subjects: 1240
Study 26553684 — intervention group
Group type: COMPARATOR
Intervention: PsACWY
Number of subjects: 1240
Study 22926800 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical block with premedication
Number of subjects: 100
Study 22926800 — intervention group
Group type: COMPARATOR
Intervention: Premedication alone (Control)
Number of subjects: 100
Study 21920208 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% enflurane
Number of subjects: 0
Study 21920208 — intervention group
Group type: COMPARATOR
Intervention: 1.2 mg/kg propofol
Number of subjects: 0
Study 19001327 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b
Number of subjects: 395
Study 19001327 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin, vinblastine, and dacarbazine (CVD) alone
Number of subjects: 395
Study 16686228 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheostomy with culture from the internal trachea wall
Number of subjects: 40
Study 12506086 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% ibopamine
Number of subjects: 30
Study 12506086 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% phenylephrine
Number of subjects: 30
Study 12506086 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% tropicamide
Number of subjects: 30
Study 10547510 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer bonding system (Fuji Ortho LC)
Number of subjects: 16
Study 10547510 — intervention group
Group type: COMPARATOR
Intervention: Composite resin bonding system (Reliance Light Bond)
Number of subjects: 16
Study 10547510 — intervention group
Group type: EXPERIMENTAL
Intervention: Both bonding systems
Number of subjects: 16
Study 8674322 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of Escherichia coli endotoxin
Number of subjects: 0
Study 8674322 — intervention group
Group type: COMPARATOR
Intervention: Intravenous administration of saline placebo
Number of subjects: 0
Study 8674322 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibuprofen (with endotoxin)
Number of subjects: 0
Study 1863928 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral therapy
Number of subjects: 168
Study 1863928 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological therapy
Number of subjects: 168
Study 1863928 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral therapy with the aid of a personal computer
Number of subjects: 168
Study 6347108 — intervention group
Group type: EXPERIMENTAL
Intervention: IV methylprednisolone 125 mg every six hours for three days
Number of subjects: 25
Study 6347108 — intervention group
Group type: EXPERIMENTAL
Intervention: IV methylprednisolone 40 mg every six hours for three days
Number of subjects: 25
Study 6347108 — intervention group
Group type: EXPERIMENTAL
Intervention: IV methylprednisolone 15 mg every six hours for three days
Number of subjects: 25
Study 6347108 — intervention group
Group type: EXPERIMENTAL
Intervention: High- and medium-dose groups combined
Number of subjects: 25
Study 28719155 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic drug treatment for 7 months
Number of subjects: 38
Study 28719155 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (CS)
Number of subjects: 38
Study 30672181 — intervention group
Group type: EXPERIMENTAL
Intervention: Methycobal iontophoresis combined with balance acupuncture
Number of subjects: 108
Study 30672181 — intervention group
Group type: COMPARATOR
Intervention: Methycobal iontophoresis
Number of subjects: 108
Study 30672181 — intervention group
Group type: COMPARATOR
Intervention: Simple balance acupuncture
Number of subjects: 108
Study 24725329 — intervention group
Group type: EXPERIMENTAL
Intervention: FFT‐CHR (18 sessions over 6 months)
Number of subjects: 103
Study 24725329 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Care (EC; 3 sessions over 1 month)
Number of subjects: 103
Study 25249568 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix 150 mg every day
Number of subjects: 252
Study 25249568 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix 75 mg twice a day
Number of subjects: 252
Study 25249568 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous depot medroxyprogesterone acetate (DMPA-SC)
Number of subjects: 252
Study 25249568 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix
Number of subjects: 252
Study 25249568 — intervention group
Group type: COMPARATOR
Intervention: DMPA-SC
Number of subjects: 252
Study 22154867 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Dialogue (PD)
Number of subjects: 2480
Study 22154867 — intervention group
Group type: COMPARATOR
Intervention: Static Patient Information (SPI)
Number of subjects: 2480
Study 20529142 — intervention group
Group type: EXPERIMENTAL
Intervention: SACMC dressing
Number of subjects: 36
Study 20529142 — intervention group
Group type: COMPARATOR
Intervention: AF dressing
Number of subjects: 36
Study 18611200 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 10
Study 18611200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 15741771 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose delivered after inhalation of 20% of vital capacity (A)
Number of subjects: 12
Study 15741771 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose delivered after inhalation of 70% of vital capacity (B)
Number of subjects: 12
Study 12424404 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 microg/kg
Number of subjects: 120
Study 12424404 — intervention group
Group type: COMPARATOR
Intervention: Droperidol 50 microg/kg
Number of subjects: 120
Study 12424404 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide 0.25 mg/kg
Number of subjects: 120
Study 9679886 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine 1.5%
Number of subjects: 52
Study 9679886 — intervention group
Group type: COMPARATOR
Intervention: Mannitol 3%
Number of subjects: 52
Study 9679886 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigant volume increase (1,000 ml)
Number of subjects: 52
Study 8085380 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined YF/ViPS vaccine (simultaneous administration)
Number of subjects: 0
Study 8085380 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined YF/ViPS vaccine (combined administration)
Number of subjects: 0
Study 8085380 — intervention group
Group type: COMPARATOR
Intervention: Single administration of ViPS vaccine
Number of subjects: 0
Study 8085380 — intervention group
Group type: COMPARATOR
Intervention: Simultaneous administration of ViPS vaccine
Number of subjects: 0
Study 8085380 — intervention group
Group type: COMPARATOR
Intervention: Combined administration of ViPS vaccine
Number of subjects: 0
Study 8085380 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines (simultaneous or combined)
Number of subjects: 0
Study 2680356 — intervention group
Group type: EXPERIMENTAL
Intervention: Timentin (3.1 g intravenously)
Number of subjects: 185
Study 2680356 — intervention group
Group type: COMPARATOR
Intervention: Mezlocillin (2.0 g intravenously)
Number of subjects: 185
Study 29955820 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver-administered ORS fluid monitoring charts
Number of subjects: 252
Study 29955820 — intervention group
Group type: COMPARATOR
Intervention: Standard care (ORS without charting)
Number of subjects: 252
Study 27842495 — intervention group
Group type: EXPERIMENTAL
Intervention: EMPOWER-PAR intervention
Number of subjects: 888
Study 27842495 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 888
Study 24637951 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of COPD
Number of subjects: 1425
Study 24637951 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD duration longer than 5 years
Number of subjects: 1425
Study 23274782 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed haemodynamic treatment (GDHT) using fluids and dobutamine to attain oxygen delivery index >600 ml min(‐1) m(‐2)
Number of subjects: 150
Study 23274782 — intervention group
Group type: COMPARATOR
Intervention: Routine fluid treatment (RFT)
Number of subjects: 150
Study 19952844 — intervention group
Group type: EXPERIMENTAL
Intervention: EGCG (135-mg)
Number of subjects: 19
Study 19952844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 18729681 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management (CM) treatments
Number of subjects: 393
Study 18729681 — intervention group
Group type: COMPARATOR
Intervention: Presence of alcohol dependence (AD)
Number of subjects: 393
Study 16901645 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl (TDF: 12.5 microg/h)
Number of subjects: 20
Study 16901645 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl (TDF: 25 microg/h)
Number of subjects: 20
Study 16901645 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal buprenorphine (TDB: 35 microg/h)
Number of subjects: 20
Study 16901645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 16901645 — intervention group
Group type: EXPERIMENTAL
Intervention: Painful electrical stimulation
Number of subjects: 20
Study 12897344 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultants who would admit patient 1 to ICU
Number of subjects: 120
Study 12897344 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultants who would admit patient 2 to ICU
Number of subjects: 120
Study 12897344 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultants who would admit patient 3 to ICU
Number of subjects: 120
Study 12897344 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold of predicted hospital survival for ICU admission recommendation
Number of subjects: 120
Study 12112946 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of asymptomatic bacterial vaginosis
Number of subjects: 0
Study 12112946 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of Trichomonas vaginalis
Number of subjects: 0
Study 9244940 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% mepivacaine plus saline (group I, n = 15)
Number of subjects: 30
Study 9244940 — intervention group
Group type: COMPARATOR
Intervention: 2% mepivacaine plus bicarbonate soda (group II, n = 15)
Number of subjects: 30
Study 8148226 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of betamethasone 17-valerate (suspension in medical grade pressure sensitive adhesive applied to a 100 cm2 area for 28 hours)
Number of subjects: 5
Study 8148226 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of 0.6 mg betamethasone
Number of subjects: 5
Study 8148226 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of betamethasone 17-valerate
Number of subjects: 5
Study 8148226 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of betamethasone
Number of subjects: 5
Study 3300292 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol (mean dose of 22 mg for 12 weeks)
Number of subjects: 15
Study 3300292 — intervention group
Group type: COMPARATOR
Intervention: Nadolol (mean dose of 103 mg for 12 weeks)
Number of subjects: 15
Study 2337121 — intervention group
Group type: EXPERIMENTAL
Intervention: NPH insulin (protamine containing)
Number of subjects: 30
Study 2337121 — intervention group
Group type: COMPARATOR
Intervention: Lente insulin (protamine free)
Number of subjects: 30
Study 1105698 — intervention group
Group type: EXPERIMENTAL
Intervention: Reserpine (5 mg i.m.)
Number of subjects: 14
Study 1105698 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (2 ml)
Number of subjects: 14
Study 31682876 — intervention group
Group type: EXPERIMENTAL
Intervention: Sports/party‐themed ads
Number of subjects: 2010
Study 31682876 — intervention group
Group type: EXPERIMENTAL
Intervention: Sports-themed ad
Number of subjects: 2010
Study 31682876 — intervention group
Group type: EXPERIMENTAL
Intervention: Party-themed ad
Number of subjects: 2010
Study 31682876 — intervention group
Group type: COMPARATOR
Intervention: Control 'product information' ads
Number of subjects: 2010
Study 30183595 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP+MTX
Number of subjects: 430
Study 30183595 — intervention group
Group type: COMPARATOR
Intervention: PBO+MTX
Number of subjects: 430
Study 28605608 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 10142
Study 28605608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10142
Study 25891484 — intervention group
Group type: EXPERIMENTAL
Intervention: Light therapy
Number of subjects: 10
Study 25891484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 23711599 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg
Number of subjects: 40
Study 23711599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 21293107 — intervention group
Group type: EXPERIMENTAL
Intervention: Daivobet®/Dovobet® gel
Number of subjects: 458
Study 21293107 — intervention group
Group type: COMPARATOR
Intervention: Tacalcitol ointment
Number of subjects: 458
Study 21293107 — intervention group
Group type: COMPARATOR
Intervention: Gel vehicle alone
Number of subjects: 458
Study 19466649 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevator metaphor
Number of subjects: 42
Study 19466649 — intervention group
Group type: EXPERIMENTAL
Intervention: Didactic learning
Number of subjects: 42
Study 19466649 — intervention group
Group type: COMPARATOR
Intervention: Active learning
Number of subjects: 42
Study 19466649 — intervention group
Group type: COMPARATOR
Intervention: Bridge metaphor
Number of subjects: 42
Study 17269993 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose proton pump inhibitor
Number of subjects: 5
Study 17269993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 15238986 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT‐11+gemcitabine (1000 mg m(‐2), days 1 and 8; CPT‐11 300 mg m(‐2), day 8)
Number of subjects: 147
Study 15238986 — intervention group
Group type: COMPARATOR
Intervention: CPT‐11 (300 mg m(‐2), day 1)
Number of subjects: 147
Study 15238986 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT‐11+gemcitabine
Number of subjects: 147
Study 15238986 — intervention group
Group type: COMPARATOR
Intervention: CPT‐11
Number of subjects: 147